CYP2C19 Genotype-Guided Antiplatelet Therapy in ST-Segment Elevation Myocardial Infarction Patients – Patient Outcome After Primary PCI - POPular Genetics

Oct 24, 2019
Font Size
A
A
A
Author/Summarized by Author:
Anthony A. Bavry, MD, MPH, FACC
Summary Reviewer:
Deepak L. Bhatt, MD, MPH, MBA, FACC
Trial Sponsor:
Netherlands Organization for Health Research and Development; Spartan Bioscience
Date Presented:
09/03/2019
Date Published:
10/24/2019
Date Updated:
10/24/2019
Original Posted Date:
09/03/2019
References

Contribution To Literature:

The POPular Genetics trial showed that a genotype-guided strategy was noninferior for net outcomes (ischemia/bleeding) and superior for bleeding (mostly minor bleeding).

Description:

The goal of the trial was to evaluate a genotype-guided strategy for selection of oral P2Y12 inhibitor compared with standard therapy with ticagrelor or prasugrel among patients undergoing primary percutaneous coronary intervention (PCI) for ST-segment elevation myocardial infarction (STEMI).

Study Design

  • Randomized
  • Parallel
  • Open-label

Patients undergoing primary PCI for STEMI were randomized to a genotype-guided strategy for selection of oral P2Y12 inhibitor (n = 1,242) versus standard therapy with ticagrelor or prasugrel (n = 1,246).

In the genotype-guided group, detection of CYP2C19*2 or CYP2C19*3 resulted in the use of ticagrelor or prasugrel. Otherwise patients received clopidogrel.

  • Total number of enrollees: 2,488
  • Duration of follow-up: 12 months
  • Mean patient age: 62 years
  • Percentage female: 26%
  • Percentage with diabetes: 12%

Inclusion criteria:

  • Patients ≥21 years of age undergoing primary PCI for STEMI

Principal Findings:

The primary net outcome of death, MI, stroke, stent thrombosis, or major bleeding (PLATO criteria) at 12 months occurred in 5.1% of the genotype-guided group compared with 5.9% of the standard care group (p for noninferiority < 0.001).

Major or minor bleeding (PLATO criteria) at 12 months occurred in 9.8% of the genotype-guided group compared with 12.5% of the standard care group (p = 0.04).

Secondary outcomes:

  • Cardiovascular death, MI, stroke, or stent thrombosis at 12 months: 2.7% of the genotype-guided group compared with 3.3% of the standard care group (p = not significant)
  • Major bleeding at 12 months (PLATO criteria): 2.3% of the genotype-guided group compared with 2.3% of the standard care group (p = not significant)
  • Major bleeding at 12 months (BARC type 3-5 criteria): 2.5% of the genotype-guided group compared with 2.3% of the standard care group (p = not significant)
  • Major bleeding at 12 months (TIMI criteria): 1.2% of the genotype-guided group compared with 1.3% of the standard care group (p = not significant)

Interpretation:

Among patients with STEMI undergoing primary PCI, a genotype-guided strategy vs. standard of care was associated with noninferiority with respect to a net composite outcome. A genotype-guided strategy was associated with superiority with respect to major or minor bleeding. However, a genotype-guided strategy was not associated with a reduction in major bleeding as defined by three criteria.

References:

Claassens DM, Vos GJ, Bergmeyer TO, et al. A Genotype-Guided Strategy for Oral P2Y12 Inhibitors in Primary PCI. N Engl J Med 2019;381:1621-31.

Editorial: Roden DM. Clopidogrel Pharmacogenetics — Why the Wait? N Engl J Med 2019;381:1677-8.

Presented by Dr. Danny Claassens at the European Society of Cardiology Congress, Paris, France, September 3, 2019.

Engage with fellow ACC members by discussing this article and ESC Congress 2019 on ACC's Member Hub message board. Please log into ACC.org to participate. Not a member? Join the ACC today!

Keywords: ESC Congress, ESC 19, Acute Coronary Syndrome, Adenosine, Anticoagulants, Genotype, Genotyping Techniques, Hemorrhage, Myocardial Infarction, Percutaneous Coronary Intervention, Standard of Care, Stents, Stroke, Thrombosis


< Back to Listings